In January 2026, Novo Nordisk appointed Maziar Doustdar as Chief Executive Officer, tasking him with sharpening the company’s focus on diabetes and obesity therapeutics. Under his leadership, management expects core products semaglutide and its obesity variant Wegovy to deliver double-digit revenue and EPS growth next year. Doustdar’s priorities include accelerating the rollout of the oral Wegovy capsule—approved in late 2025—and reallocating R&D resources toward next-generation GLP-1 candidates. Investors will watch his ability to sustain gross margin above 80% while funding planned increases in production capacity across three new European and North American fill-finish sites.

Novo Nordisk’s pipeline now includes amycretin (a single-molecule GLP-1 agonist) in Phase 1 and CagriSema (a semaglutide‐amylin dual agonist) in late-stage clinical trials, both designed to surpass current weight-loss efficacy benchmarks. Since 2021 the company has invested over DKK 10 billion in strategic M&A, acquiring Dicerna Pharmaceuticals for DKK 22 billion to secure RNAi capabilities and Inversago Pharma for up to DKK 7 billion to strengthen its rare‐disease arm. Management has indicated another DKK 5–10 billion war chest for bolt-on deals in cardiovascular and metabolic disorders through 2027.

International patent expirations for semaglutide are scheduled in Canada and China during 2026, placing pressure on list prices in those markets. Novo Nordisk has negotiated a three-year pricing agreement under U.S. most-favored-nation provisions, which will cap price increases for its GLP-1 therapies in Medicaid by tying maximum allowed prices to the lowest OECD comparator. To offset anticipated mid-single‐digit percentage revenue declines in affected jurisdictions, the company plans to leverage volume growth from expanded China distribution—where obesity drug approvals doubled patient access in H2 2024—and to up‐list branded rebates to key wholesalers.

In fiscal 2024 Novo Nordisk reported revenues of DKK 290.4 billion (up 25% year-over-year) and net income of DKK 101.0 billion, supported by a 40% rebound in share value following the 2025 sell-off. The company’s long-range plan forecasts obesity treatment sales growing from DKK 90 billion in 2024 to over DKK 200 billion by 2030, representing an annualized growth rate above 15%. Capital expenditures are projected at DKK 15–18 billion for 2026, focused on manufacturing scale-up and digital patient support platforms, while R&D spend is budgeted at 12% of sales to sustain a mid-teens adjusted operating margin through the decade.